Objective To investigate the efficacy and safety of low dose tirofiban combined with reteplase in the thrombolytic treatment of young and middle-aged patients with acute myocardial infarction (AMI).Methods A total of 120 AMI patients were selected and randomly divided into group A and group B,60 cases in each group.The patients in the group A were given reteplase combined with low dose of tirofiban [0.05 μg/(kg·min)],and the patients in the group B were given reteplase combined with routine dose of tirofiban [0.1 μg/(kg·min)].The vascular recanalization rate,the platelet aggregation rate,the levels of coagulation and fibrinolysis related indicators,the main clinical events and bleeding complications were compared between two groups.Results The vascular recanalization rate of group A was 76.67%,which was similar to 81.67% of group B (P>0.05).After treatment,the platelet aggregation rate were significantly lower than that before treatment in both groups (P<0.05).After treatment,the levels of Fg and D-D were significantly lower than those before treatment in both groups,and the levels of PLT and t-PA were significantly higher than those before treatment (P<0.05).After one month of treatment,there was no significant difference in incidence rate of clinical events between two groups (P>0.05).The incidence rate of bleeding complications in group A was significantly lower than the group B (P<0.05).Conclusion The thrombolytic effect of low dose tirofiban on treatment of AMI is similar to that of the conventional dose,but it can reduce the risk of bleeding and improve medication safety.

Objective To investigate the efficacy and safety of low dose tirofiban combined with reteplase in the thrombolytic treatment of young and middle-aged patients with acute myocardial infarction (AMI).Methods A total of 120 AMI patients were selected and randomly divided into group A and group B,60 cases in each group.The patients in the group A were given reteplase combined with low dose of tirofiban [0.05 μg/(kg·min)],and the patients in the group B were given reteplase combined with routine dose of tirofiban [0.1 μg/(kg·min)].The vascular recanalization rate,the platelet aggregation rate,the levels of coagulation and fibrinolysis related indicators,the main clinical events and bleeding complications were compared between two groups.Results The vascular recanalization rate of group A was 76.67%,which was similar to 81.67% of group B (P>0.05).After treatment,the platelet aggregation rate were significantly lower than that before treatment in both groups (P<0.05).After treatment,the levels of Fg and D-D were significantly lower than those before treatment in both groups,and the levels of PLT and t-PA were significantly higher than those before treatment (P<0.05).After one month of treatment,there was no significant difference in incidence rate of clinical events between two groups (P>0.05).The incidence rate of bleeding complications in group A was significantly lower than the group B (P<0.05).Conclusion The thrombolytic effect of low dose tirofiban on treatment of AMI is similar to that of the conventional dose,but it can reduce the risk of bleeding and improve medication safety.